Regeneron is commited to discovering and validating new drug targets.
At Regeneron there is a strong commitment to fueling the pipeline with new targets that are discovered or validated in Regeneron's research laboratories. Regeneron Research Laboratories, headed by George D. Yancopoulos, MD, PhD, is staffed with leading scientists with expertise in several therapeutic areas.
Regeneron therapeutic areas:
- Angiogenesis
- Oncology
- Ophthalmology
- Cardiovascular Diseases
- Immunity and Inflammation
- Infectious Diseases
- Metabolic Diseases and Obesity
- Muscle Disorders
- Pain
- Bone Disease
Highlights
Using its platform technologies, Regeneron scientists have investigated and validated new targets that can be translated into new product candidates.
VelocImmune® is being used to generate fully-human monoclonal antibodies to address clinically relevant
targets of therapeutic interest.
Traps are designed to trap specific extracellular signaling molecules (such as cytokines and growth factors) and may be used
to block the activity of these molecules in certain disease settings.